Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- UPMC Western Maryland — Cumberland, Maryland
- FMH James M Stockman Cancer Institute — Frederick, Maryland
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, su…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06661720
Sites in Maryland: - UPMC Western Maryland — Cumberland, Maryland
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Maryland: - Maryland Proton Treatment Center — Baltimore, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- UM Upper Chesapeake Medical Center — Bel Air, Maryland
- Central Maryland Radiation Oncology in Howard County — Columbia, Maryland
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Maryland: - Greater Baltimore Medical Center — Baltimore, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland
- FMH James M Stockman Cancer Institute — Frederick, Maryland
Phase 2 Recruiting Academic/Other
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with re…
Sponsor: NRG Oncology
NCT ID: NCT05327686
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Central Maryland Radiation Oncology in Howard County — Columbia, Maryland
- UM Baltimore Washington Medical Center/Tate Cancer Center — Glen Burnie, Maryland
Phase 2 Recruiting Network
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Dru…
Sponsor: Children's Oncology Group
NCT ID: NCT04322318
Sites in Maryland: - Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting NIH
This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first starte…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05896839
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07293351
Sites in Maryland: - Local Institution - 0123 — Baltimore, Maryland
Phase 2 Recruiting NIH
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby t…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04981509
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
- NCI - Center for Cancer Research — Bethesda, Maryland
Phase 1, Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out whether the combination of abemaciclib and cabozantinib is a safe and effective treatment for people with metastatic clear cell renal cell carcinoma (ccRCC) and translocation-associated rena…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06835972
Sites in Maryland: - Johns Hopkins University (Data Collection Only) — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
Single arm, single site, open-label Phase II study of the effects of oral olaparib in participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, C…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT03786796
Sites in Maryland: - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Phase 2 Recruiting NIH
Background: Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough people to conduct large trials for new treatments. Two drugs-sac…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06161532
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments. Better treatments are needed. Objective: To test a pair of drugs (sasanlimab an…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05665361
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is call…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT02830724
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting NIH
Background: Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melanoma. Researchers want to see if these drugs can be used together to produce bette…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05155033
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Maryland: - Exelixis Clinical Site #14 — Baltimore, Maryland
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Maryland: - American Oncology Partners, P.A. - The Center for Cancer & Blood Disorders — Bethesda, Maryland
- Maryland Oncology Hematology — Silver Spring, Maryland
Phase 1 Recruiting Industry
The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and…
Sponsor: Arcus Biosciences, Inc.
NCT ID: NCT05536141
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Phase 1 Recruiting Industry
The study will assess the safety, PK, PD, and preliminary efficacy of ABBVCLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (T…
Sponsor: Calico Life Sciences LLC
NCT ID: NCT04777994
Sites in Maryland: - Johns Hopkins Hospital /ID# 254056 — Baltimore, Maryland
Phase 1 Recruiting NIH
Background: Genitourinary cancers are some of the most common types of cancer. They are lethal when they spread. The drug M7824 blocks the paths that cancer cells use to stop the immune system from fighting cancer. The drug PDS01ADC trigge…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04235777
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1 Recruiting Academic/Other
This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT07062549
Sites in Maryland: - Johns Hopkins University — Baltimore, Maryland
Phase 1 Recruiting NIH
Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Research…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06479811
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Maryland: - Mercy Medical Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
- University of Maryland Shore Medical Center at Easton — Easton, Maryland
Recruiting Network
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going ca…
Sponsor: Children's Oncology Group
NCT ID: NCT02402244
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Maryland: - Massive Bio SYNERGY-AI site — Baltimore, Maryland
- Massive Bio SYNERGY-AI site — Bethesda, Maryland
- Massive Bio SYNERGY-AI site — Silver Spring, Maryland
- Massive Bio SYNERGY-AI site — Towson, Maryland